Life
Senator Investigates FDA as BioNTech Founders Depart for New Venture
The co-founders of BioNTech are leaving to establish a new mRNA-focused company, prompting a U.S. senator to investigate the FDA's oversight.
Editorial Staff
1 min read
On March 10, 2026, it was reported that the co-founders of BioNTech, recognized for their development of a Covid-19 vaccine, will be departing the company.
Their new venture will concentrate on mRNA technology, which has significant implications for vaccine development and public health infrastructure.
In light of these developments, a U.S. senator is probing the FDA's actions regarding its regulatory oversight of the biotech sector, raising questions about the agency's role in fostering innovation.